Ascrinvacumab
| Monoclonal antibody | |
|---|---|
| Type | ? |
| Source | Human |
| Target | activin receptor-like kinase 1 |
| Clinical data | |
| Other names | PF-03446962 |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6396H9850N1694O2012S44 |
| Molar mass | 144079.64 g·mol−1 |
Ascrinvacumab (PF-03446962) is a monoclonal antibody designed for the treatment of cancer.[1] It is an ALK1 inhibitor.[2]
This drug was developed by Pfizer Inc.
References
[edit]- ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Ascrinvacumab, American Medical Association.
- ^ de Vinuesa AG, Bocci M, Pietras K, Ten Dijke P (August 2016). "Targeting tumour vasculature by inhibiting activin receptor-like kinase (ALK)1 function". Biochemical Society Transactions. 44 (4): 1142–1149. doi:10.1042/BST20160093. PMID 27528762.
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |